Spero Therapeutics (SPRO) Other Gross PP&E Adjustments (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Other Gross PP&E Adjustments data on file, last reported at -$2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 41.5% year-over-year to -$2.2 million; the trailing twelve-month figure through Mar 2026 stood at -$2.2 million (up 41.5% YoY), and the FY2025 full-year result was -$2.1 million, down 25.46% from the prior year.
• Other Gross PP&E Adjustments for Q1 2026 stood at -$2.2 million, down from -$2.1 million in the prior quarter.
• Across five years, Other Gross PP&E Adjustments topped out at -$1.2 million in Q4 2023 and bottomed at -$7.8 million in Q1 2022.
• The 5-year median for Other Gross PP&E Adjustments is -$4.0 million (2024), against an average of -$4.1 million.
• The widest annual swing landed in 2024, when Other Gross PP&E Adjustments slumped 36.2%; it then soared 47.48% in 2025.
• A 5-year view of Other Gross PP&E Adjustments shows it stood at -$2.2 million in 2022, then soared by 43.5% to -$1.2 million in 2023, then slumped by 36.2% to -$1.7 million in 2024, then slipped by 25.46% to -$2.1 million in 2025, then decreased by 1.41% to -$2.2 million in 2026.
• The last three Other Gross PP&E Adjustments figures came in at -$2.2 million (Q1 2026), -$2.1 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.

Peer Comparison